Dianthus Therapeutics, Inc.
DNTH
株式のランク
#3912
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
株価
$75.21
最終同期: 2026-10-19
時価総額
$4.21B
変化（1日）
4.33%
変化（1年）
108.93%
国
US
取引 Dianthus Therapeutics, Inc. (DNTH)
カテゴリー
Healthcare
Dianthus Therapeutics, Inc.（DNTH）のP/B比率
October 2026 時点のP/B比率 TTM: 3.57
Dianthus Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 3.57 です。2023 年末時点でのP/B比率は 0.32 でした。
Dianthus Therapeutics, Inc. の P/B 比率の履歴（2016 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
